Cataplexy associated with narcolepsy: Epidemiology, pathophysiology and management

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Although narcolepsy was first described over 100 years ago, most of what is known about the pathological changes in the CNS that are responsible for this unusual disease has been learned during the past few years. It is now known that narcolepsy is caused by the loss of a relatively few neurons that are responsible for producing the neuropeptide hypocretin in the CNS. The onset of narcolepsy typically occurs in early adulthood and may consist of a variety of symptoms; however, cataplexy (an abrupt, bilateral loss of skeletal muscle tone) is most specific to narcolepsy. TCAs were found to be beneficial for the treatment of cataplexy over 40 years ago and, more recently, the SSRIs have been used to treat the condition. The recent availability of sodium oxybate (the first drug to receive regulatory approval for the treatment of cataplexy) represents a significant advance in the treatment of narcolepsy, as it is highly efficacious for the treatment of cataplexy and shows promise for the treatment of excessive sleepiness and for improving sleep quality in patients with narcolepsy.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalCNS Drugs
Volume20
Issue number1
DOIs
StatePublished - 2006

Fingerprint

Cataplexy
Narcolepsy
Epidemiology
Sodium Oxybate
Therapeutics
Neuropeptides
Sleep
Skeletal Muscle
Neurons
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Cataplexy associated with narcolepsy : Epidemiology, pathophysiology and management. / Thorpy, Michael J.

In: CNS Drugs, Vol. 20, No. 1, 2006, p. 43-50.

Research output: Contribution to journalArticle

@article{62b1c9581d5e4f3a904c342a6f6c6a6f,
title = "Cataplexy associated with narcolepsy: Epidemiology, pathophysiology and management",
abstract = "Although narcolepsy was first described over 100 years ago, most of what is known about the pathological changes in the CNS that are responsible for this unusual disease has been learned during the past few years. It is now known that narcolepsy is caused by the loss of a relatively few neurons that are responsible for producing the neuropeptide hypocretin in the CNS. The onset of narcolepsy typically occurs in early adulthood and may consist of a variety of symptoms; however, cataplexy (an abrupt, bilateral loss of skeletal muscle tone) is most specific to narcolepsy. TCAs were found to be beneficial for the treatment of cataplexy over 40 years ago and, more recently, the SSRIs have been used to treat the condition. The recent availability of sodium oxybate (the first drug to receive regulatory approval for the treatment of cataplexy) represents a significant advance in the treatment of narcolepsy, as it is highly efficacious for the treatment of cataplexy and shows promise for the treatment of excessive sleepiness and for improving sleep quality in patients with narcolepsy.",
author = "Thorpy, {Michael J.}",
year = "2006",
doi = "10.2165/00023210-200620010-00004",
language = "English (US)",
volume = "20",
pages = "43--50",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Cataplexy associated with narcolepsy

T2 - Epidemiology, pathophysiology and management

AU - Thorpy, Michael J.

PY - 2006

Y1 - 2006

N2 - Although narcolepsy was first described over 100 years ago, most of what is known about the pathological changes in the CNS that are responsible for this unusual disease has been learned during the past few years. It is now known that narcolepsy is caused by the loss of a relatively few neurons that are responsible for producing the neuropeptide hypocretin in the CNS. The onset of narcolepsy typically occurs in early adulthood and may consist of a variety of symptoms; however, cataplexy (an abrupt, bilateral loss of skeletal muscle tone) is most specific to narcolepsy. TCAs were found to be beneficial for the treatment of cataplexy over 40 years ago and, more recently, the SSRIs have been used to treat the condition. The recent availability of sodium oxybate (the first drug to receive regulatory approval for the treatment of cataplexy) represents a significant advance in the treatment of narcolepsy, as it is highly efficacious for the treatment of cataplexy and shows promise for the treatment of excessive sleepiness and for improving sleep quality in patients with narcolepsy.

AB - Although narcolepsy was first described over 100 years ago, most of what is known about the pathological changes in the CNS that are responsible for this unusual disease has been learned during the past few years. It is now known that narcolepsy is caused by the loss of a relatively few neurons that are responsible for producing the neuropeptide hypocretin in the CNS. The onset of narcolepsy typically occurs in early adulthood and may consist of a variety of symptoms; however, cataplexy (an abrupt, bilateral loss of skeletal muscle tone) is most specific to narcolepsy. TCAs were found to be beneficial for the treatment of cataplexy over 40 years ago and, more recently, the SSRIs have been used to treat the condition. The recent availability of sodium oxybate (the first drug to receive regulatory approval for the treatment of cataplexy) represents a significant advance in the treatment of narcolepsy, as it is highly efficacious for the treatment of cataplexy and shows promise for the treatment of excessive sleepiness and for improving sleep quality in patients with narcolepsy.

UR - http://www.scopus.com/inward/record.url?scp=30344472431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344472431&partnerID=8YFLogxK

U2 - 10.2165/00023210-200620010-00004

DO - 10.2165/00023210-200620010-00004

M3 - Article

C2 - 16396523

AN - SCOPUS:30344472431

VL - 20

SP - 43

EP - 50

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 1

ER -